Citations

Showing 10 of 108152 citations.

A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis
Wen, Ya-Ting, Wu, Alexander T.H. , Bamodu, Oluwaseun Adebayo , Li, Wei , Lin, Chien‐Min , Chao, Tsu-Yi, Hsiao, Michael , Huang, Hsu‐Shan , Huang, Hsu-Shan , Wu, Alexander T H , Wen, Ya-Ting , Yen, Yun , Mukhopadhyay, Debabrata , Huang, Hsu-Shan

Mayo Clinic

Cancers | September 27, 2019 | Volume: 11 | Issue: 10 | Pages: 1442

10.3390/cancers11101442 | PMID 31561595 Get It

The management of glioblastomas (GBMs) is challenged by the development of therapeutic resistance and early disease recurrence, despite multi-modal therapy. This may be attributed to the presence of glioma stem cells (GSCs) which are known to survive radio- and chemotherapy, by circumventing death signals and inducing cell re-population. Recent findings suggest GSCs may be enriched by certain treatment modality. These necessitate the development of novel therapeutics capable of targeting GBM cell plasticity and therapy-resistant GSCs. Here, aided by computer-assisted structure characterization and target identification, we predicted that a novel 5-(2′,4′-difluorophenyl)-salicylanilide derivative, LCC-09, could target dopamine receptors and oncogenic markers implicated in GBMs. Bioinformatics data have indicated that dopamine receptor (DRD) 2, DRD4, CD133 and Nestin were elevated in GBM clinical samples and correlated to TMZ (Temozolomide) resistance and increased ALDH (Aldehyde dehydrogenase) activity (3.5–8.9%) as well as enhanced (2.1–2.4-fold) neurosphere formation efficiency in U87MG and D54MG GBM cell lines. In addition, TMZ-resistant GSC phenotype was associated with up-regulated DRD4, Akt, mTOR, β-catenin, CDK6, NF-κB and Erk1/2 expression. LCC-09 alone, or combined with TMZ, suppressed the tumorigenic and stemness traits of TMZ-resistant GBM cells while concomitantly down-regulating DRD4, Akt, mTOR, β-catenin, Erk1/2, NF-κB, and CDK6 expression. Notably, LCC-09-mediated anti-GBM/GSC activities were associated with the re-expression of tumor suppressor miR-34a and reversal of TMZ-resistance, in vitro and in vivo. Collectively, these data lay the foundation for further exploration of the clinical feasibility of administering LCC-09 as single-agent or combinatorial therapy for patients with TMZ-resistant GBMs.
LINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2
Song, Zhiwang , Zhang, Xia , Lin, Yun , Wei, Youzhen , Liang, Shujing , Dong, Chunyan

Mayo Clinic

Journal of Cellular and Molecular Medicine | September 27, 2019 | Volume: 23 | Issue: 11 | Pages: 7554-7565

10.1111/jcmm.14625 | PMID 31557401 Get It

AbstractMounting evidence highlights long non‐coding RNAs (lncRNAs) as crucial regulators in multiple types of biological processes and contributing to tumourigenesis. LINC01133, located in chromosome 1q23.2, was a recently identified novel lncRNA with a length of 1154nt. It was involved in the development of colorectal cancer and non‐small cell lung cancer. However, its clinical relevance, biological functions and potential molecular mechanism in breast cancer are still unclear. In this study, we found that the LINC01133 expression was significantly down‐regulated in breast cancer samples and was associated with progression and poor prognosis of breast cancer. Further experiments demonstrated that overexpression of LINC01133 inhibited invasion and metastasis in breast cancer both in vitro and in vivo. Mechanistic investigations revealed that LINC01133 repressed SOX4 expression by recruiting EZH2 to SOX4 promoter. Moreover, rescue experiments further confirmed that LINC01133 functional acted as an anti‐oncogene, at least partly, via repressing SOX4 in breast cancer. Taken together, these findings imply that LINC01133 could serve as a novel prognostic biomarker and potential therapeutic target for breast cancer.
Pericardial Manifestations in Inflammatory Bowel Disease: A Report of Two Cases
Qazi, Taha , Christian, Kaci E., Cross, Raymond, Farraye, Francis A.

Mayo Clinic

Crohn's & Colitis 360 | September 27, 2019 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/crocol/otz028 Get It

Abstract Pericardial involvement in the setting of inflammatory bowel disease can occur not only as an adverse event related to medical therapy but also as an extraintestinal manifestation of the disease itself. In the following case series, we describe 2 cases of pericarditis in patients diagnosed with Crohn disease. Our first case reviews the clinical presentation of acute pericarditis as an adverse event associated with anti-tumor necrosis factor therapy. In contrast, our second patient is a case of acute pericarditis as a precursor of the clinical recurrence of Crohn disease following operative resection. Pericardial disease should be considered in the differential diagnosis of acute and subacute presentations of chest discomfort and shortness of breath in patients with inflammatory bowel disease.
Fluorescence in‐situ hybridisation for TP63 rearrangements in T cell lymphomas: single‐site experience of 470 patients and implications for clinical testing
Peterson, Jess F. , Pearce, Kathryn E., Meyer, Reid G., Greipp, Patricia T. , Knudson, Ryan A., Feldman, Andrew L. , Feldman, Andrew L , Peterson, Jess F , Greipp, Patricia T , Baughn, Linda B. , Ketterling, Rhett P.

Mayo Clinic

Histopathology | September 27, 2019 | Volume: 76 | Issue: 3 | Pages: 481-485

10.1111/his.14005 | PMID 31557339 Get It

AimsThe aims of this study were to review our 5‐year experience with clinical FISH testing for TP63 rearrangements using both TP63 break‐apart (BAP) and TBL1XR1/TP63 dual‐fusion (D‐FISH) probes to evaluate the frequency of TP63 rearrangements and the distribution of TBL1XR1 vs. alternate partner loci, and to assess whether both probe sets are necessary in all cases undergoing FISH testing.Methods and resultsA retrospective review of the Mayo Clinic cytogenetic database identified 470 patients evaluated by FISH testing for TP63 rearrangements in formalin‐fixed paraffin‐embedded (FFPE) tissue using both BAP and D‐FISH probes. Of these, 25 (5.3%) had TP63 rearrangements. All samples were being investigated for anaplastic large‐cell lymphoma or other T cell lymphoma subtypes. A TBL1XR1 partner was identified by D‐FISH in 12 (48%) of 25 cases. All cases positive by TBL1XR1/TP63 D‐FISH were also positive by TP63 BAP FISH.ConclusionThis is the largest series of TP63 rearrangements to date. The frequency of positive results among cases referred to a large reference laboratory for TP63 FISH testing was 5.3%. Approximately half of TP63 rearrangements have a TBL1XR1 partner. TP63 BAP FISH testing is sufficient for up‐front testing of FFPE tissue samples. However, because of the genomic proximity of the TP63 and TBL1XR1 loci, we recommend reflex TBL1XR1/TP63 D‐FISH testing in positive and equivocal cases.
Plastic stents for refractory pancreatic duct strictures in chronic pancreatitis: the more the merrier
Chandrasekhara, Vinay

Mayo Clinic

Endoscopy | September 26, 2019 | Volume: 51 | Issue: 10 | Pages: 911-912

10.1055/a-0997-3053 | PMID 31557771 Get It

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial
Dueck, Amylou C. , Scher, Howard I. , Mazza, Gina L. , Thanarajasingam, Gita , Schwab, Gisela, Weitzman, Aaron, Rogak, Lauren J. , Basch, Ethan , Dueck, A. C. , Mazza, Gina L , Bennett, Antonia V , Basch, Ethan

Mayo Clinic

JAMA Oncology | September 26, 2019 | Volume: 6 | Issue: 2 | Pages: e193332

10.1001/jamaoncol.2019.3332 | PMID 31556911 Get It

Ten Eleven Things Not to Say to Your Female Colleagues
Borrero‐Mejias, Clarimar, Starling, Amaal J. , Burch, Rebecca , Loder, Elizabeth , Minen, Mia T. , Rastogi, Reena Gogia , Gautreaux, Jessica , Nahas, Stephanie J. , Monteith, Teshamae , Monteith, Teshamae S , Minen, Mia T , Metzler, Abby

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 26, 2019 | Volume: 59 | Issue: 10 | Pages: 1846-1854

10.1111/head.13647 | PMID 31557320 Get It

Do Shared Decision-Making Measures Reflect Key Elements of Shared Decision Making? A Content Review of Coding Schemes
Kunneman, Marleen , Henselmans, Inge , Gärtner, Fania R. , Bomhof‐Roordink, Hanna , Pieterse, Arwen H.

Mayo Clinic

Medical Decision Making | September 26, 2019 | Volume: 39 | Issue: 7 | Pages: 886-893

10.1177/0272989x19874347 | PMID 31556799 Get It

Background. There is a growing need for valid shared decision-making (SDM) measures. We aimed to determine whether the items of extant SDM observer-based coding schemes assess the 4 key elements of SDM. Methods. Items of SDM coding schemes were extracted and categorized. Except for the 4 key elements of SDM (fostering choice awareness, informing about options, discussing patient preferences, and making a decision), (sub)categories were created inductively. Two researchers categorized items independently and in duplicate. Results. Five of 12 coding schemes assessed all 4 SDM elements. Seven schemes did not measure “fostering choice awareness,” and 3 did not measure “discussing patient preferences.” Seventy of 194 items (36%) could not be classified into one of the key SDM elements. Items assessing key SDM elements most often assessed “informing about options” ( n = 57/124, 46%). Conclusion. Extant SDM coding schemes often do not assess all key SDM elements and have a strong focus on information provision while other crucial elements of SDM are underrepresented. Caution is therefore needed in reporting and interpreting the resulting SDM scores.
Letter by Mishra et al Regarding Article, “Infection as a Stroke Trigger: Associations Between Different Organ System Infection Admissions and Stroke Subtypes”
Lal, Amos , George, Anu Anna , Lal, Amos , Mishra, Ajay Kumar

Mayo Clinic

Stroke | September 26, 2019 | Volume: 50 | Issue: 11 | Pages: No page available

10.1161/strokeaha.119.026990 | PMID 31554499 Get It